Literature DB >> 28916854

[No improved survival with adjuvant chemotherapy in node negative rectal cancer after radiochemotherapy].

Gunther Klautke1.   

Abstract

Entities:  

Mesh：

Year:  2017        PMID： 28916854     DOI： 10.1007/s00066-017-1208-8

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN： 0179-7158            Impact factor:   3.621


× No keyword cloud information.
  4 in total

1.  Postoperative chemotherapy may not be necessary for patients with ypN0-category after neoadjuvant chemoradiotherapy of rectal cancer.

Authors:  Rainer Fietkau; Malte Barten; Gunther Klautke; Ernst Klar; Kaja Ludwig; Hartmut Thomas; Wolfgang Brinckmann; Andreas Friedrich; Friedrich Prall; Gernot Hartung; Ute Küchenmeister; Gunther Kundt
Journal:  Dis Colon Rectum       Date:  2006-09       Impact factor: 4.585

2.  Adjuvant chemotherapy following neoadjuvant therapy of rectal cancer: the type of neoadjuvant therapy (chemoradiotherapy or radiotherapy) may be important for selection of patients.

Authors:  Rainer Fietkau; Gunther Klautke
Journal:  J Clin Oncol       Date:  2008-01-20       Impact factor: 44.544

3.  Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy (ADORE): an open-label, multicentre, phase 2, randomised controlled trial.

Authors:  Yong Sang Hong; Byung-Ho Nam; Kyu-Pyo Kim; Jeong Eun Kim; Seong Joon Park; Young Suk Park; Joon Oh Park; Sun Young Kim; Tae-You Kim; Jee Hyun Kim; Joong Bae Ahn; Seok-Byung Lim; Chang Sik Yu; Jin Cheon Kim; Seong Hyeon Yun; Jong Hoon Kim; Jin-Hong Park; Hee Chul Park; Kyung Hae Jung; Tae Won Kim
Journal:  Lancet Oncol       Date:  2014-09-04       Impact factor: 41.316

4.  Chronicle: results of a randomised phase III trial in locally advanced rectal cancer after neoadjuvant chemoradiation randomising postoperative adjuvant capecitabine plus oxaliplatin (XELOX) versus control.

Authors:  R Glynne-Jones; N Counsell; P Quirke; N Mortensen; A Maraveyas; H M Meadows; J Ledermann; D Sebag-Montefiore
Journal:  Ann Oncol       Date:  2014-04-08       Impact factor: 32.976
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.